• Citer

Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the phase III randomized, double-blind ECHO and THRIVE trials

par Nelson, Mark;Amaya, Gerardo;Clumeck, Nathan ;Arns da cunha, Clovis;Jayaweera, Dushyantha;Junod, Patrice;Li, Taisheng;Tebas, Pablo;Stevens, Marita;Buelens, Annemie;Vanveggel, Simon;Boven, Katia;Abusamra, Lorena;Cahn, Pedro;Laplume, Héctor;Cassetti, Isabel;Ceriotto, Mariana;Martins, M.D.;Krolewiecki, Alejandro;Amarilis Lugo, L.;Bolan, Robert;Bush, Larry Marc;Corales, Roberto Baun;Crane, Lawrence Richard;De Vente, J.;Fischl, Margaret A.;Gathe, Joseph;Greenberg, Richard;Henry, Kenneth;Jayaweera, D.;Kumar, Princy Suresh;Lalezari, Jacob;Leider, Jason;Lubelchek, Ronald Jay;Martorell, Claudia;Mounzer, Karam;Cohen, Calvin;Olivet, Hannah;Ortiz, Reinaldo;Rhame, Frank;Roberts, Afsoon;Ruane, Peter;Scribner, Anita;Segal-Maurer, Sorana;Short, William;Sloan, Louis;Wilkin, Timothy;Wohlfeiler, Michael;Yangco, Bienvenido
Référence Journal of antimicrobial chemotherapy, 67, 8, page (2020-2028), dks130
Publication Publié, 2012-08

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques